ArticleAmerican journal of translational research2026
Application value of CT-based extracellular volume fraction in assessing microsatellite status in colorectal cancer.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the application value of computed tomography (CT)-derived extracellular volume fraction (ECV) for predicting microsatellite instability (MSI) status in colorectal cancer (CRC).
methodsWe enrolled a total of 121 consecutive patients with CRC who underwent curative resection. Prior to surgery, each patient underwent a contrast-enhanced CT scan for ECV quantification. MSI status was determined by immunohistochemistry or polymerase chain reaction. Univariate and multivariate techniques of logistic regression analysis were conducted to find the independent predictors. Three predictive models were developed and compared: ECV-only, clinical, and combined. Model performance was assessed using receiver operating characteristic curves, DeLong test, calibration curves, and decision curve analysis.
resultsThe mean ECV% of the MSI-high group (n = 28) was significantly higher than that of the MSS group (n = 84) (P<0.001). Significant difference was noted among MSI-H, MSI-L (n = 9), and MSS groups (F = 8.37; P<0.001). Based on multivariate analysis, tumor diameter ≥5 cm, N0 stage and higher ECV% were independent predictors. As per the results, the combination model had an AUC of 0.81 (95% CI: 0.72-0.90), which was higher than the other models but the differences were statistically not significant (P = 0.051 and P = 0.135). The model demonstrated solid calibration and positive net clinical benefit between 10% and 80% threshold probabilities.
conclusionCT derived ECV is significantly associated with MSI status in CRC. A non-invasive preoperative model for predicting microsatellite instability that combines ECV, tumor diameter and N stage has a promising diagnostic accuracy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.